SCHEMBL2012836

SCHEMBL2012836

C=Cc1cc(C(=O)O)c(-c2cccc(F)c2)c2ncccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
KDM4A O75164 2/20 0.41
EGLN1 Q9GZT9 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM6B O15054 1/20 0.41
KDM6A O15550 1/20 0.41
TET3 O43151 1/20 0.41
KDM4B O94953 1/20 0.41
KDM5C P41229 1/20 0.41
KDM4D Q6B0I6 1/20 0.41
TET2 Q6N021 1/20 0.41
ALKBH5 Q6P6C2 1/20 0.41
TET1 Q8NFU7 1/20 0.41
FTO Q9C0B1 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
KDM3A Q9Y4C1 1/20 0.41
DHODH Q02127 3/20 0.41
KMO O15229 2/20 0.40
IL1B P01584 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2011275 0.90 TOP2A (0.40) KDM4EL3MBTL1KMOIL1BRAB9A
SCHEMBL2011974 0.87 KDM4E (0.46) KDM4EDHODHPDE4ACDC7ROCK2
SCHEMBL2012478 0.84 TRPM8 (0.42) KDM4EDHODHPDE4ACDC7ROCK2
SCHEMBL2011277 0.79 CDC7 (0.37) KDM4EL3MBTL1RAB9APDE4APDE4B
SCHEMBL2015215 0.74 L3MBTL1 (0.44) KDM4EL3MBTL1KMORAB9APDE4A
SCHEMBL2012706 0.73 TOP2A (0.42) KDM4EDHODHKMOIL1BPDE4A
SCHEMBL2015003 0.72 PIK3CD (0.46) KDM4EL3MBTL1RAB9AALDH1A1LMNA
SCHEMBL2015835 0.71 KDM4E (0.43) KDM4EPDE4APDE4BPDE4CPDE4D
SCHEMBL22446564 0.70 COMT (0.50) KDM4EL3MBTL1RAB9AALDH1A1LMNA
SCHEMBL2012014 0.70 KDM4E (0.48) KDM4EL3MBTL1DHODHCDC7ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 KDM4E 1058/4885KDM4A 1180/4885EGLN1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.